1. bookVolumen 14 (2021): Heft 1 (June 2021)
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
1313-9053
Erstveröffentlichung
08 Sep 2014
Erscheinungsweise
2 Hefte pro Jahr
Sprachen
Englisch
Uneingeschränkter Zugang

Granulocytic Expression of CD11b/CD18 and Thrombotic Risk in Patients with Myeloproliferative Neoplasms

Online veröffentlicht: 12 Jul 2021
Volumen & Heft: Volumen 14 (2021) - Heft 1 (June 2021)
Seitenbereich: 47 - 52
Eingereicht: 03 Sep 2020
Akzeptiert: 22 Apr 2021
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
1313-9053
Erstveröffentlichung
08 Sep 2014
Erscheinungsweise
2 Hefte pro Jahr
Sprachen
Englisch

1. Gamal TE, Mohamed G, Omina S, Mahmoud MK. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. Int J Clin Exp Pathol. 2015;8(9):11555-9. Search in Google Scholar

2. Da Silva RR, Hatzlhofer BLD, Machado CGF, Lima ASM, Albuquerque DM, Santos MNN et al. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. Genet Test Mol Biomarkers. 2012;16(7):802-5.10.1089/gtmb.2011.027222304488 Search in Google Scholar

3. Azevedo A, Silva SN, Reichert A, Lima F, Júnior E., Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. J. Biomedical Reports. 2017;7(4):370-6.10.3892/br.2017.977564958629085634 Search in Google Scholar

4. Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015;1(1):97-105.10.1001/jamaoncol.2015.8926182311 Search in Google Scholar

5. Levine RL. Mechanisms of mutations in myeloproliferative neoplasms. Best Pract Res Clin Haematol. 2009;22(4):489-94.10.1016/j.beha.2009.08.00619959098 Search in Google Scholar

6. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676–82.10.1182/blood-2005-09-382616373657 Search in Google Scholar

7. Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, Kongruang A, Limsuwanachot N, Sirirat T et al. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. Asian Pacific journal of cancer prevention: APJCP. 2016;17(10):4647-53. Search in Google Scholar

8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweget JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.10.1056/NEJMoa05111315858187 Search in Google Scholar

9. Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011;2(6):485-90.10.18632/oncotarget.281324820521646683 Search in Google Scholar

10. Barbui T, Finazzi G, Falanga A; Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-84.10.1182/blood-2013-03-46015423823316 Search in Google Scholar

11. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.10.1182/blood-2009-08-23895619965680 Search in Google Scholar

12. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275-90.10.1111/j.1365-2141.2004.05277.x15667529 Search in Google Scholar

13. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-51.10.3324/haematol.1334618790799 Search in Google Scholar

14. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchiolie R еt al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310-3.10.1182/blood-2006-09-04634217110452 Search in Google Scholar

15. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol. 2005;42(4):239-47.10.1053/j.seminhematol.2005.05.02316210037 Search in Google Scholar

16. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143-51.10.1034/j.1600-0609.2001.00359.x11350482 Search in Google Scholar

17. Alvarez-Larrán A, García-Pagán JC, Abraldes JG, Arellano E, Reverter JC, Bosch J et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol. 2004;124(3):329-35.10.1046/j.1365-2141.2003.04770.x14717780 Search in Google Scholar

18. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261-6.10.1182/blood.V96.13.4261 Search in Google Scholar

Empfohlene Artikel von Trend MD

Planen Sie Ihre Fernkonferenz mit Scienceendo